缬沙坦治疗早期糖尿病肾病82例临床观察

The influence of valsartan on MAU of patients with diabetic nephropathy（DN） at early stage

目的 探讨缬沙坦治疗早期糖尿病肾病（DN）的临床疗效及安全性.方法 163例早期DN患者按入院顺序随机分为治疗组82例和对照组81例,两组均给予常规治疗,治疗组加用缬沙坦治疗,60～80 mg/d,疗程为24周.观察比较两组微量白蛋白尿排泄率（UAER）、血清肌酐（Cr）、尿素氮（BUN）等变化情况及不良反应发生情况.结果 治疗24周后,治疗组UAER、Cr、BUN分别为（142.4±15.6）μg/min、（68.7±9.4）μmol/L、（3.5±1.2）mmol/L,较治疗前的（195.8±23.7）μg/min、（93.8±13.6）μmol/L、（6.3±1.5）mmol/L明显改善（t=13.675、11.287、2.469,均P〈0.05）,较对照组治疗24周后的（199.6±24.7）μg/min、（87.7±11.3）μmol/L、（6.2±1.3）mmol/L降低更明显（t=13.246、10.312、2.518,均P〈0.05）.两组均未发生严重不良反应.结论 缬沙坦治疗早期糖尿病肾病可以有效改善患者肾功能,提高治疗效果,且不良反应较少.

Objective To explore influence of valsartan on MAU of patients with DN at early stage.Methods 163 patients with DN at early stage were randomly divided into experimental group and control group.Two groups were given routine therapy, and experimental group were added the therapy of valsartan.Period of treatment was 24 weeks, and compared the UAER, Cr, BUN of two groups.Results After treatment of 24 weeks, UAER, Cr, BUN of experimental groups was （142.4 ± 15.6） μg/min, （ 68.7 ±9.4） μmol/L, （3.5 ± 1.2 ） mmol/L, compared with （195.8±23.7）（μg/min,（93.8 ± 13.6） μmol/L, （6.3 ±1.5） mmol/L before treatment, had significant difference （t = 13.675,11.287,2.469,all P〈0.05）.Compared with（ 199.6 ±24.7）μg/min,（87.7 ±11.3）μmol/L、（6.2 ± 1.3）mmol/L of control group after treatment, declined more significantly （t = 13.246,10.312,2.518,all P〈0.05）.There was no serious complications occurred in two groups.Conclusion Valsartan used in patients with DN at early stage,can significantly improve the function of kidney and enhance clinical effect,decline the side reaction.